Fluosol

Fluosol is an artificial blood substitute and oxygen-carrying emulsion composed primarily of two perfluorochemicals—perfluorodecalin and perfluorotripropylamine. It is formulated as a 20% intravascular perfluorochemical emulsion designed to deliver oxygen to tissues during periods of ischemia or severe anemia. The drug acts by dissolving and transporting high concentrations of oxygen; after administration, the majority of the compound is eliminated via expiration through the lungs. Fluosol was developed in Japan and first tested in the United States in patients who refused blood transfusions for religious reasons. Its primary indications included use as an adjunct during procedures such as percutaneous transluminal coronary angioplasty (PTCA) to preserve myocardial function during transient ischemia, treatment of severe anemia when transfusion was not possible, and experimental use for acute cerebral ischemia. Other potential uses investigated included limiting myocardial infarct size and sensitizing tumors to chemotherapy or radiotherapy. Adverse effects include ventricular arrhythmias, pruritus, bradycardia, chest pain, dyspnea, increased respiratory rate, immune suppression risk due to phagocytic activation of neutrophils by its detergent component Pluronic F-68[1][2][3][5][6].

Brand names

Fluosol

Other names

perfluorochemical emulsionperfluorocarbon blood substituteFluosol-DA 20%FDA (Fluosol DA-20%)